/
On August 15, 2011, we changed our name from Stem Cell Assurance, Inc. to BioRestorative Therapies, Inc. We develop therapeutic products using cell and tissue protocols, primarily involving adult stem cells. 3 We are currently pursuing our Disc/Spine Program with our initial investigational therapeutic product being called BRTX-100 .
The business is unprofitable at the operating level (-4350.05% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 10.3% YoY. Margins deteriorated 1468.5pp alongside, both lines moving the wrong way.
ROIC dropped from -97.64% to -278.15%, capital efficiency is deteriorating. Negative free cash flow of -$11M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$358K
▼ -10.3% YoY
Net Income (TTM)
-$11M
▼ -58.6% YoY
Op. Margin
-3975.00%
▼ -1468.5pp YoY
ROIC
-430.79%
▼ -180.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$12M
▼ -30.8% YoY
Op. Cash Flow (TTM)
-$12M
▼ -31.1% YoY
Net Debt
-$4M
Net Cash Position
Cash & Equiv.
$4M
5Y CAGR: +36.1%
Continue Research